FDA Approves First Therapy for Allergic Fungal Rhinosinusitis - Takeaways - MDSpire

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

Patients with allergic fungal rhinosinusitis now have a targeted biologic option.

  • By

  • Kathryn Wighton

  • February 25, 2026

  • 2 min

Share

  • 1

    Dupilumab is the first FDA-approved therapy for allergic fungal rhinosinusitis in patients aged 6 years and older.

  • 2

    The condition affects up to 8% of patients with chronic sinus inflammation and is characterized by thick mucus accumulation.

  • 3

    Dupilumab treatment improved sinus opacification, nasal polyp size, nasal congestion, and olfactory function over 52 weeks.

  • 4

    The therapy reduced the need for systemic corticosteroids and sinus surgery, and decreased sinus bone erosion.

  • 5

    Common adverse reactions to dupilumab include injection-site reactions, eosinophilia, insomnia, and toothache.

Original Source(s)

FDA Approves First Therapy for Allergic Fungal Rhinosinusitis

  • by Kathryn Wighton

  • February 25, 2026

Related Content

Post-pandemic resurgence of Mycoplasma pneumoniae and its emerging link with Rhinovirus in children

AD Not Linked to Early CV Risk Markers

Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.

Electroencephalographic abnormalities and clinical phenotypes in children with autism spectrum disorder: a single center cohort study